BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 33634350)

  • 21. A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.
    Liang R; Gao GX; Chen JP; Wang JS; Wang XM; Zeng Y; Bai QX; Zhang T; Yang L; Dong BX; Gu HT; Shu MM; Hao CX; Wang JH; Zhang N; Chen XQ
    Hematol Oncol; 2017 Dec; 35(4):619-629. PubMed ID: 27723108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of
    Sun N; Qiao W; Xing Y; Wang T; Yang J; Zhao J
    Clin Transl Oncol; 2021 Aug; 23(8):1571-1576. PubMed ID: 33449269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study.
    Jiang C; Liu J; Li L; Kosik RO; Su M; Zou L; Tian R
    Nucl Med Commun; 2017 Nov; 38(11):937-947. PubMed ID: 28858180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weakly supervised deep learning for determining the prognostic value of
    Guo R; Hu X; Song H; Xu P; Xu H; Rominger A; Lin X; Menze B; Li B; Shi K
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3151-3161. PubMed ID: 33611614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
    Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
    Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of an
    Wang H; Zhao S; Li L; Tian R
    Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary tumor standardized uptake value (SUVmax) measured on
    Hui Z; Wei F; Ren H; Xu W; Ren X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lymph node standardized uptake values at pre-treatment
    Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
    Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
    Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
    Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
    [No Abstract]   [Full Text] [Related]  

  • 31. The exact Deauville score, NABS score and high SUVmax predicts outcome in extranodal natural killer/T-cell lymphoma.
    Huang HL; Ngam PI; Tan KM; Ng DCE; Lim ST; Chan JY
    Ann Nucl Med; 2021 May; 35(5):557-568. PubMed ID: 33683545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
    Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
    Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic activity of extranodal NK/T cell lymphoma on
    Lim CH; Yoon SE; Kim SJ; Cho J; Ko YH; Lee KH; Kim WS
    Sci Rep; 2021 Mar; 11(1):5879. PubMed ID: 33723329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.
    Bai B; Huang HQ; Cai QC; Fan W; Wang XX; Zhang X; Lin ZX; Gao Y; Xia YF; Guo Y; Cai QQ; Jiang WQ; Lin TY
    Med Oncol; 2013 Mar; 30(1):339. PubMed ID: 23329306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
    Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value of
    Luo Y; Huang Z; Gao Z; Wang B; Zhang Y; Bai Y; Wu Q; Wang M
    Korean J Radiol; 2024 Feb; 25(2):189-198. PubMed ID: 38288898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
    Dai N; Liu H; Deng S; Sang S; Wu Y
    Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.